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The synthesis and biological evaluation of the stable isotope containing chemotactic peptide, deutero- 
formyl-methionyl-leucyl-phenylakmine (C’DO-Met-Leu-Phe-OH) is reported. The results, using 
lysosomal enzyme release from cytochalasin B-treated rabbit neutrophils for biological evaluation 
indicates a 3-4 fold enhancement over CHO-Met-Leu-Phe-OH itself. This is consistent with previous 
speculation that the formyl proton hydrogen bonds with a critical area of the chemotactic peptide receptor 
of rabbit neutrophils. 
Chemotactic peptide Lysosomal enzyme release 
1. INTRODUCTION 
W-Formyl-methionyl-leucyl-phenylalanine 
(CHO-Met-Leu-Phe-OH) is the prototype of a 
series of small molecular mass oligopeptides which 
stimulate chemotaxis, lysosomal enzyme secretion 
and a variety of other cellular responses in mam- 
malian phagocytes [1,2]. These effects are 
mediated by interaction of the peptide with a 
specific membrane receptor [3,4] the structural re- 
quirements of which have been summarized [5]. 
This summary, expressed as a hypothetical model 
of the receptor of rabbit neutrophils, included 
speculation about several specific interactions bet- 
ween the tripeptide and its receptor. In light of the 
almost absolute requirement for the presence of 
the formyl group it was postulated that the marked 
enhancement produced by formylation was the 
result of hydrogen bonding of the formyl proton 
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with a critical area on the receptor. As a test of this 
hypothesis we have attempted to determine if the 
well-known stable isotope enhancement of 
hydrogen bonding seen with some enzyme-sub- 
strate interactions [6] would also be evident with 
this ligand-receptor interaction. Accordingly, we 
have synthesized deutero-formyl-methionyl-leu- 
cyl-phenylalanine (@DO-Met-Leu-Phe-OH). 
This analog has been evaluated analytically, re- 
lative to CHO-Met-Leu-Phe-OH, and for its 
ability to induce lysosomal enzyme secretion from 
rabbit neutrophils. 
2. EXPERIMENTAL 
The tripeptide benzyl ester, H-Met-Leu-Phe- 
OBzl was prepared by a rapid mixed anhydride 
method using isobutylchloroformate [71. 
Deuteroformic acid (Merck) was coupled via a 
conventional anhydride procedure using 
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isovaleryl-chloride as in [9]. Final deprotection was 
with anhydrous hydrogen fluoride/anisole (45 
min, 4°C) and the compound was purified by 
crystallization from acetone/HzO. The compound 
was compared to CHO-Met-Leu-Phe-OH by: 
(i) Thin-layer chromatography (by vol.) [System 
(A) benzene: HzO: acetic acid (9:l.g); system 
(B), N-butanol:HzO: acetic acid (4: 1: 1); 
system (C) chloroform:methanol:H20:acetic 
acid (60:30:1:4)]; 
(ii) Melting point; 
(iii) Nuclear magnetic resonance (NMR) spec- 
troscopy in DMSO. 
In addition, by amino acid analysis (Beckman 
119C) the compound was also found to contain the 
appropriate residues in a 1: 1: 1 molar ratio. 
Lysosomal enzyme release was determined for 
both CHO-Met-Leu-Phe-OH and C2DO- 
Met-Leu-Phe-OH using cytochalasin-B-treated 
rabbit neutrophils as in [l]. 
3. RESULTS 
The synthesis of C2DO-Met-Leu-Phe-OH pro- 
ceeded uneventfully although by a different route 
than reported for CHO-Met-Leu-Phe-OH [8]. 
Side-by-side comparison of the deuterated analog 
and authentic CHO-Met-Leu-Phe-OH showed 
that the two were indistinguishable with respect o 
chromatographic mobility and melting point (table 
Table 1 
Analytical comparison of CHO-Met-Leu-Phe-OH and 
C’DO-Met-Leu-Phe-OH 
CHO-Met-Leu- C’DO-Met-Leu- 
Phe-OH Phe-OH 
Thin-layer mobility (I?$ 
system A 0.66 0.66 
system B 0.67 0.67 
system C 0.68 0.68 
Melting point (“C) 213-215 211-212 
‘System A = benzene:water:acetic a id (9:1:9, by vol.); 
system B = n-butanol:water:acetic acid (4: 1: 1, by vol.); 
system C = chloroform:methanol:water:acetic acid 
(60:30:1:4, by vol.). 
Mixtures of the two peptides also gave a single spot in 
each system. 
Fig. 1. Lysosomal enzyme secretion from cytochalasin 
B-treated rabbit neutrophils. Concentration dependency 
for C’DO-Met-Leu-Phe-OH (A) and CHO- 
Met-Leu-Phe-OH (0). Each point is the average of S 
determinations, done in duplicate, each of which had 
SEM of <S%. 
1). Furthermore, a NMR spectrum of C2DO- 
Met-Leu-Phe-OH was obtained in DMSO and 
compared to that reported for CHO- 
Met-Leu-Phe-OH [lo]. The results indicated 
that, with the exception of the total absence of the 
formyl proton resonance, the position and relative 
intensity of the other resonances were identical for 
both peptides. 
The results of the biological evaluation are 
shown in fig. 1 and clearly indicate a significantly 
enhanced activity for the deuterated analog. The 
apparent affinities (i.e., the concentration to 
produce 50% of the maximum effect) were 
1.5 x lo-” M (CHO-Met-Leu-Phe-OH) and 
3.0 x 10-l’ M (C2DO-Met-Leu-Phe-OH), re- 
spectively. There was a similar decrease in the 
threshold concentration for C’DO-Met-Leu-Phe- 
OH but no change in the maximum effect. Overall, 
this isotopic substitution results in a 4-5-fold 
enhancement in the biological activity of the 
deuterated analog vs CHO-Met-Leu-Phe-OH. 
4. DISCUSSION 
When stable isotopes are introduced into 
substrates at sites known to hydrogen bond, 
enhancement of the enzyme-substrate interaction 
is well documented to occur [6]. In an effort to test 
our hypothesis that the proton of the formyl group 
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was hydrogen bonding with the receptor, we at- 
tempted to demonstrate a similar enhancement 
following deuterium substitution into CHO- 
Met-Leu-Phe-OH. As indicated, this substitution 
did indeed enhance biological activity and to about 
the same extent (4-5-fold) as with enzyme-sub- 
strate interactions. 
Obviously, biological activity of any complex 
ligand is a function both of the 3-dimensional 
structure of the ligand and the effectiveness of the 
interaction with its receptor. Any chemical altera- 
tion may therefore be expected to change either or 
both of these determinants. The unequivocal 
answer to the question posed here then requires 
that no change in the conformation result from the 
deuterium substitution. That this is the case is 
strongly supported by the finding that the NMR 
spectrum, less the formyl proton resonance, of the 
deuterated analog is identical to that of authentic 
CHO-Met-Leu-Phe-OH [ 101. It should be noted, 
however, that the spectra were taken in DMSO and 
therefore do not take into account peptide-solvent 
interactions in physiological buffers. As further 
evidence of this ‘identity’ we note the identical 
mobility in a variety of thin-layer chromatography 
systems and the closeness of the melting points. 
In summ~y, we have prepared C2D0-Met- 
Leu-Phe-OH and found it to be indistinguishable 
from CHO-Met-Leu-Phe-OH in all ways except 
for its enhanced biological activity. This we believe 
is good evidence in support of the hypothesis that 
the formyl proton hydrogen bonds with the recep- 
tor of rabbit neutrophils. In addition to its specific 
use we also submit that stable isotope substitutions 
may be useful probes to evaluate ligand-receptor 
interactions in general. 
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